Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330596 | 0.83 | MIF (0.61) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL2141861 | 0.82 | MIF (0.77) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL13667975 | 0.77 | SLC6A4 (0.47) | CYP3A4SLC6A4MAOASLC6A2SLC6A3 | |
| SCHEMBL1706732 | 0.77 | MIF (0.63) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL9610849 | 0.77 | MIF (0.63) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL8763362 | 0.76 | MIF (0.68) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL9678076 | 0.76 | MIF (0.56) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL13764448 | 0.73 | MIF (0.49) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL1457562 | 0.72 | MIF (1.00) | MIFTRPA1CYP3A4ALDH1A1HPGD | |
| SCHEMBL895951 | 0.72 | MIF (0.64) | MIFTRPA1CYP3A4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | MIF 277/4885TRPA1 601/4885CYP3A4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.